Immunotherapy before surgery for small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of small cell lung cancer (SCLC) that is surgically removable (stage I to IIIB).
- You must not have had any prior treatment for your lung cancer (like chemotherapy, radiation, or surgery).
- Your cancer must not have spread to your brain or other organs.
- You must be healthy enough to undergo lung surgery, with good heart and lung function, and no active autoimmune diseases or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
This trial tests whether adding immunotherapy (PD-L1/PD-1 inhibitors) to standard chemotherapy before surgery helps people with limited-stage small cell lung cancer. The goal is to see if the combination shrinks the tumor more effectively than chemotherapy alone.
This Phase 3 trial tests whether adding a drug called adebrelimab (SHR-1316) to standard chemotherapy before treatment leads to more successful surgery and/or radiation for limited-stage small cell lung cancer. It’s for people who have not had any prior cancer treatment and can undergo planned “curative” treatment after 4 cycles.
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy, with or without another drug (bevacizumab), given before surgery for people with a certain type of lung cancer. The goal is to see if this combination helps shrink the tumor and makes surgery more effective.
Hear when a new Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.